Business Context and Reporting Period
Company: Lifecore Biomedical, Inc. (LFCR)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Fiscal Quarter and Nine Months Ended February 23, 2025
Business Overview: A fully integrated contract development and manufacturing organization (CDMO) specializing in sterile injectable pharmaceutical products and premium pharmaceutical-grade sodium hyaluronate (HA). The company operates as a single reportable segment.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Feb 23, 2025 | Nine Months Ended Feb 23, 2025 | Nine Months Ended Feb 25, 2024 |
|---|---|---|---|
| Total Revenues | $35,154 | $92,423 | $90,375 |
| Gross Profit | $9,845 | $26,316 | $24,578 |
| Gross Margin | 28.0% | 28.5% | 27.2% |
| Operating Loss | $(9,029) | $(22,572) | $(10,993) |
| Net Loss | $(14,769) | $(37,570) | $19,096 (Income) |
| Cash and Cash Equivalents | $5,417 | As of Feb 23, 2025 | |
| Net Cash Used in Operating Activities | $(5,553) (9 months) | $(8,459) (9 months) | |
| Total Debt (Principal) | $184,361 | $187,539 | |
| Related Party Debt (Principal) | $169,287 (Term Loan) | $157,313 |
Material Changes vs. Prior Period
- Revenue Mix: Total revenue for the nine months increased 2% to $92.4 million. This was driven by a 13% increase in HA manufacturing revenue ($25.8M) due to supply chain initiatives by a major customer, partially offset by a 1% decline in CDMO revenue ($66.6M) due to customer terminations and project cycle completions.
- Operating Expenses: Operating expenses increased significantly. Selling, General, and Administrative (SG&A) expenses rose 24% year-over-year for the nine-month period, primarily due to a $3.8 million increase in stock-based compensation and $9.5 million in legal fees related to legacy matters (SEC subpoena, activist investor, class action).
- Asset Disposal Loss: The company recorded a $6.9 million loss on the sale or disposal of assets, primarily a $6.4 million loss on the sale of an isolator-filler that had not yet been installed, involving the write-off of capitalized interest costs.
- Profitability Shift: The company reported a net loss of $37.6 million for the nine months ended Feb 23, 2025, compared to a net income of $19.1 million in the prior year period. The prior year included $2.7 million in income from discontinued operations (Curation Foods settlement) which is absent in the current period.
Guidance, Outlook, Risks, and Unusual Items
- Legal Contingencies: The company faces multiple legal challenges, including an investor dispute filed by 22NW Fund seeking damages and specific performance regarding preferred stock conversion caps, and a putative securities class action lawsuit. The company intends to vigorously defend these claims. Additionally, the SEC issued a subpoena in February 2024 regarding a financial statement restatement.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of February 23, 2025, due to material weaknesses in internal control over financial reporting. Remediation efforts include hiring qualified personnel, engaging third-party consultants, and implementing a new ERP system.
- Debt Derivative Liability: A significant non-operating item is the "Change in fair value of debt derivative liability, related party." This resulted in a $1.5 million gain for the nine months ended Feb 23, 2025, compared to a $41.9 million gain in the prior year. This volatility is driven by changes in the probability of a change-in-control event.
- Liquidity: As of February 23, 2025, the company had $5.4 million in cash and approximately $25.5 million available under its Revolving Credit Facility. Management believes these resources are sufficient for the next 12 months.
- Subsequent Event: On March 24, 2025, the company agreed to resolve a historical lease obligation from the Curation Foods business, expecting a gain of $2.5 million in the fourth quarter of fiscal 2025.
Investor Verification Checklist
- Related Party Concentration: Verify the sustainability of revenue from Alcon Research, LLC, which accounted for 43% of revenues for the nine months ended Feb 23, 2025, and is also the primary lender on the Term Loan Credit Facility.
- Debt Covenants: Confirm ongoing compliance with the minimum liquidity covenant ($4.5 million) under the Term Loan Credit Facility and the springing fixed charge ratio covenant under the Revolving Credit Facility.
- Legal Exposure: Monitor the status of the 22NW Fund lawsuit and the securities class action, as potential damages could be material and are currently not estimable.
- Internal Control Remediation: Track the progress of the ERP implementation and the remediation of material weaknesses in internal controls, as failure to remediate could impact future reporting reliability.
- Inventory Valuation: Review the $2.5 million fluctuation in inventory adjustments to net realizable value noted in the gross profit analysis, as this indicates potential obsolescence risks.